


# PORTEC-3 / EN7

---



- *uniform schedule*
- *upfront pathology review*
- *QoL analysis*




# Eligibility

---

- *Endometrial carcinoma FIGO 2009:*
  - » *stage IA with invasion, grade 3, LVSI+*
  - » *stage IB grade 3*
  - » *stage II*
  - » *stage IIIA or IIIC, IIIB<sub>parametrium</sub>*
  - » *stage IA<sub>invasion</sub>, IB, II or III and serous or clear cell*
- *WHO PS 0-2*
- *no residual macroscopic tumor after surgery*
- *Pathology review before randomisation*



# Accrual



# Accrual – 1 Oct 2013

| Group        | Arm 1      | Arm 2      | Total      | Past year  |
|--------------|------------|------------|------------|------------|
| Netherlands  | 69         | 73         | 142        | 23         |
| Italy        | 47         | 51         | 98         | 18         |
| Australia/NZ | 58         | 50         | 108        | 24         |
| Canada       | 55         | 8          | 63         | 13         |
| UK           | 94         | 81         | 175        | 47         |
| France       | 34         | 30         | 64         | 9          |
| <b>Total</b> | <b>330</b> | <b>329</b> | <b>659</b> | <b>134</b> |

**Closing December 2013**



# PORTEC-3 international collaboration



**Thank you**

**PORTEC - 3**  
*International Intergroup Trial*

